Erectile Dysfunction Market Assessment & Analysis 2007-2022 : Market Research Report

Erectile Dysfunction Market Assessment & Analysis 2007-2022

Published by: Visiongain

Published: Feb. 1, 2008 - 85 Pages

Chapter 1 Executive Summary
Chapter 2 Introduction - The Erectile Dysfunction Market Will See Large Growth Rates Throughout the Period, 2007-2012: 2.1 The Viagra Revolution; 2.2 Erectile Dysfunction Defined; 2.3 ED Prevalence is Increasing; 2.4 Male Hormonal Changes Due to Age; 2.5 How an Erection Occurs; 2.6 Penile Anatomy and Erection; 2.7 Primary and Secondary ED; 2.8 The Causes of Secondary ED; 2.9 ED Due to Systemic Diseases and Ageing; 2.10 Neurogenic Erectile Dysfunction; 2.11 Vascular Causes of Erectile Dysfunction; 2.12 Drug-Induced Erectile Dysfunction; 2.13 Summary of All ED Treatments; 2.14 Drug Therapy
Chapter 3 The World Market for ED Drugs: 3.1 The ED Market Will See Large Growth Rates; 3.2 Viagra Will Lose Dominance of the ED Market; 3.3 Cialis Will Achieve Blockbuster Status; 3.4 Viagra Will Lose Market Dominance to Cialis; 3.5 Levitra Shows Strong Growth; 3.6 Shortest Time to Erection is a Major Market Advantage; 3.7 Brand Awareness Will Play a Key Part in Maintaining Viagra's Position in the Market; 3.8 Brand Switching Will Increase Individual Drug Sales But Not Expand the Market; 3.9 Market Expansion Depends on Persuading ED Men to Seek Treatment 3.10 Pfizer Currently Leads the ED Market; 3.11 The US Dominates the World Market for ED Drugs
Chapter 4 Forces Affecting the ED Market: 4.1 SWOT Analysis of the ED Market; 4.2 An Expanding Patient Population Constitutes the Principal Driver in the ED Market; 4.3 The Principal Restraints in the ED Market; 4.4 Major Success in the ED Drugs Market and Opportunities to Target; 4.5 Adverse Events Over ED Drugs; 4.6 Lack of Adequate Reimbursement Limits Potential of ED Drugs; 4.7 ED Surgery - A Last Resort When Drug-Based Treatments Fail; 4.8 ED Awareness is Key for Market Expansion; 4.9 Uprima (Apomorphine) is a Market Failure
Chapter 5 Female Sexual Dysfunction (FSD) and Future Market Possibilities: 5.1 Female Sexual Arousal; 5.2 Over 45% of All Women Will Experience Some Degree of FSD; 5.3 Genital Vascular Congestion Essential for Normal Sexual Function in Both Men and Women; 5.4 The Medical Causes of Female Sexual Dysfunction; 5.5 Medical Drugs Can Cause FSD; 5.6 There are Times in a Women's Life of Natural Decreased Sexual Desire; 5.7 The Treatments for Female Sexual Dysfunction; 5.8 The Role of Estrogen and Progesterone in Female Sexual Desire is not Understood; 5.9 The Role of Testosterone in Female Sexual Desire is Not Clear 5.10 The Treatment of Female Sexual Arousal Disorders; 5.11 Anorgasmia Responds Well to Therapy; 5.12 The Successful Treatment for Dyspareunia Approaches 90%; 5.13 The Pharmacological Treatment of FSD and Future Market Possibilities
Chapter 6 Pipeline Developments in the Erectile Dysfunction Market: 6.1 Abbott's ABT- 670 in Phase I Trials for ED; 6.2 Agents in Phase II of Clinical Development; 6.3 SK Chemicals' Mirodenafil in Pre-Registration for ED; 6.4 New Drugs for ED Must Have a Short Onset Time; 6.5 Discussion of Current Pipeline Developments; 6.6 Summary of Pipeline Drugs for ED, Phase I and Above
Chapter 7 The Counterfeit ED Drugs Market: 7.1 Drug Counterfeiting: An Overview; 7.2 The Different Types of Counterfeit Drugs; 7.3 Viagra Counterfeits; 7.4 Country Specific Patent Laws and How it can Influence Drug; Counterfeiting; 7.5 The Growth of Internet Pharmacies Has Aided Viagra Sales; 7.6 The Privacy Factor as a Driver of Online Sales; 7.7 Online Viagra; 7.8 Internet Erectile Dysfunctional Drugs Sales; 7.9 Combating the Counterfeiters
Chapter 8 Conclusion: 8.1 ED is a Serious Condition with High Prevalence; 8.2 ED Market Analysis; 8.3 Market Drivers; 8.4 Market Restraints; 8.5 New Products May Not Expand the Market Further; 8.6 The Time to Erection is the Most Important Aspect of Any Novel ED Drug; 8.7 The Key to Market Expansion is to Get More ED Men to Seek Medical Advise; 8.8 Strategies for Marketing: Changing Men's Minds; 8.9 Outlook for the Future of the ED Market
List of Tables: Table 1.1 Top ED Drugs Revenue ($m), 2006; Table 2.1 Major Drug Therapies for ED, 2006; Table 2.2 Viagra, Cialis, and Levitra Revenues ($m) and Market Share; (%), 2006; Table 3.1 The Total World ED Drugs Market Forecast ($m), 2007-2012; Table 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012; Table 3.3 The Worldwide Market Share by Revenue (%) for ED Drugs,; 2007-2012; Table 3.4 Viagra, Levitra and Cialis: Specific Product Advantages, 2007; Table 3.5 Top 10 Leading Companies in the ED Market, Revenue ($m) and; Market Share (%), 2006; Table 3.6 Market Share by Country Region by Revenue (%), 2006; Table 4.1 A SWOT Chart for the ED Market; Table 5.1 Types of Female Sexual Dysfunction and Prevalence; Table 5.2 Drugs that Cause Decreased Sexual Desire; Table 5.3 Drugs that Cause Decreased Sexual Arousal; Table 6.1 Agents in Phase II of Clinical Development for ED, 2007; Table 6.2 Summary of Pipeline Drugs for ED, Phase I and Above, 2007
List of Figures: Figure 2.1 Worldwide Revenues ($m) for the ED Market, 2007-2012; Figure 3.1 Total ED Drugs World Market Revenue Forecast ($m), 2007-2012; Figure 3.2 Worldwide Revenues ($m) for ED Drugs, 2007-2012; Figure 3.3 The Worldwide Market Share (%) By Revenue for Viagra, Levitra; and Cialis, 2007-2012; Figure 3.4 Market Share (%) by Revenue of ED Drugs, 2006; Figure 3.5 Market Share (%) by Revenue of ED Drugs, 2009; Figure 3.6 Market Share (%) by Revenue of ED Drugs, 2012; Figure 3.7 Leading Companies in the ED Market, Market Share (%), 2006; Figure 3.8 Market Share by Country Region (%), 2006; Figure 8.1 Total Sales of ED Drugs ($m), 2007-2012; Figure 8.2 Sales of the Leading ED Drugs ($m), 2007-2012

Abstract

The market for Erectile Dysfunction (ED) drugs is growing fast with a CAGR of 4.9% for the period 2006-2012. The ED market contains three leading drugs Viagra, Levitra and Cialis. Viagra, already a blockbuster drug, is the most popular and recognised brand on the market.

Furthermore, high revenues are predicted by visiongain for the top three ED drugs, with Cialis reaching blockbuster status by 2007. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints. The purpose of this market analysis by visiongain is to examine prospects for Erectile Dysfunction (ED) drugs from 2007-2022, including sales forecasts for leading pharmaceutical products.

Most men experience ED at some points in their lives usually by the age of 40, but are not necessarily psychologically affected by it. Some men, however, experience chronic and complete ED. Over 150 million men worldwide are unable to achieve and maintain an erection adequate for satisfactory sexual intercourse; visiongain expects this figure to double by 2020. Despite its commonplace occurrence, ED is a notoriously under-reported, under-recognised, and an under-treated chronic illness.

It is estimated that 85% to 90% of all ED goes undiagnosed.

The ED Market Report examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The ED Market concentrates on the following essential aspects of the market:

Discussion of the current pharmaceutical market
Forecast of the worldwide pharmaceutical market from 2007-2012
Drivers and restraints facing the ED market
Opportunities and threats facing the ED market
Growth of the ED drugs market between 2007-2012
Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012
The potential of generics manufacturers to penetrate this market
Pipeline developments with blockbuster potential
Currently marketed drugs with blockbuster potential
Discussion of unmet therapeutic needs and relative advantages of products

Why you should buy this report:

To receive a comprehensive analysis of the prospects for ED drugs from 2007-2012
To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2007-2012
To determine key activities of leading companies
To discover "hot" pipeline developments and up-and-coming products
To determine the forces that influence the market for ED products:
Competitive characteristics of the market
Drivers
Restraints
Strengths, weaknesses, opportunities and threats (SWOT analysis)
To find out where the ED market is heading - both technologically and commercially

Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in the ED Market. Amongst the catalogue of products in the ED pipeline is transdermal therapies. Neew innovative products for ED has generated a high level of interest from; top-tier companies, the major players in the ED circle and niche companies alike.

This visiongain report is the single tool to equip you with the latest trends in all regional markets and why drug companies are aiming for a new generation of drugs. Visiongain recommends this astute report to the major players in the field as it will arm you with the clinical challenges that larger companies face to date, thus the rising inherent cost of R&D expenditure to in order meet the requirements set by major regulatory authorities for larger evidence of clinical data before any authorisation.

The ED Market Assessment & Analysis 2007-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics.

Unique benefits to you when you order this report:

Primary research throughout. You will not find this information anywhere else
Report stored in your reading room for ever
Full searchable report when you buy the company or corporate editions
Copies can be printed off for offline reading
Packed with charts, analysis, figures, graphs and tables

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Erectile Dysfunction Market Assessment & Analysis 2007-2022

Table of Contents

Abstract